Adlai Nortye Group (ANL) vs Inventiva S.A. American Depository Shares (IVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, gaining 572.6% versus a loss of 39.4%. Adlai Nortye Group is the larger company by market cap ($710.3 million vs $694.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | IVA |
|---|---|---|
| Share price | $11.03 | $2.94 |
| Market cap | $710.31M | $694.49M |
| 1-day change | -8.77% | -5.47% |
| YTD return | +676.76% | -36.77% |
| 1-year return | +572.56% | -39.38% |
| 5-year return | — | -79.35% |
| EPS (TTM) | $-0.66 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-51.87M | $-49.63M |
| 52-week high | $17.25 | $7.98 |
| 52-week low | $0.879 | $2.82 |
| Distance from 52-week high | -36.06% | -63.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +167.45% | +417.01% |
| Average volume | 212.90K | 1.61M |
| Shares outstanding | 58.73M | 236.22M |
| Employees | 109 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed IVA by 611.9 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ANL vs IVA FAQ
Which is bigger, Adlai Nortye Group or Inventiva S.A. American Depository Shares?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $710.31M compared with $694.49M for Inventiva S.A. American Depository Shares (IVA).
Which stock has performed better over the past year, ANL or IVA?
ANL returned +572.56% over the past 12 months, compared with -39.38% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Inventiva S.A. American Depository Shares in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.